Drug Profile
VTP 201227
Alternative Names: VTP-201227Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Vitae Pharmaceuticals
- Class Antipsoriatics; Skin disorder therapies
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne; Psoriasis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 11 Jan 2011 Discontinued - Phase-II for Psoriasis in USA (Topical)
- 11 Jan 2011 Discontinued - Preclinical for Acne in USA (Topical)